KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short-term Investments (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Short-term Investments data on record, last reported at $114.4 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 455.89% year-over-year to $114.4 million; the TTM value through Dec 2025 reached $114.4 million, up 455.89%, while the annual FY2025 figure was $114.4 million, 455.89% up from the prior year.
  • Short-term Investments reached $114.4 million in Q4 2025 per RIGL's latest filing, up from $88.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $114.4 million in Q4 2025 and bottomed at $9.4 million in Q3 2024.
  • Average Short-term Investments over 5 years is $48.4 million, with a median of $32.6 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: tumbled 77.82% in 2023, then skyrocketed 840.45% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $106.1 million in 2021, then crashed by 68.19% to $33.7 million in 2022, then fell by 28.45% to $24.1 million in 2023, then fell by 14.79% to $20.6 million in 2024, then surged by 455.89% to $114.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $114.4 million in Q4 2025, $88.6 million in Q3 2025, and $55.0 million in Q2 2025.